Journal of International Oncology››2015,Vol. 42››Issue (7): 485-487.doi:10.3760/cma.j.issn.1673-422X.2015.07.002
Previous ArticlesNext Articles
Xue Kewei, Li Guixin, Li Xinxin, Guo Yingxue, Li Ao, Wang Wenhao
Online:
2015-07-08Published:
2015-05-26Contact:
Li Guixin E-mail:liguixin@wfmc.edu.comXue Kewei, Li Guixin, Li Xinxin, Guo Yingxue, Li Ao, Wang Wenhao. Effect of umbilical cord blood dendritic cells induced by gastric cancer antigen combined with CIK cells in gastric cancer cell lines SGC-7901[J]. Journal of International Oncology, 2015, 42(7): 485-487.
[1] Sastre J, GarciaSaenz JA, DiazRubio E. Chemotherapy for gastric cancer[J]. World J Gastroenterol, 2006, 12(2): 2004-2013. [2] Lion E, Smits EL, Berneman ZN. NK cells: key to success of DCbased cancer vaccines[J]. Oncologist, 2012, 17(10): 1256-1270. [3] Mann DL, Celluzzi CM, Hankey KG, et al. Combining conventional therapies with intratumoral injection of autologous dendritic cells and activated T cells to treat patients with advanced cancers[J]. Ann N Y Acad Sci, 2009, 1174(1): 41-50. [4] Gao D, Xie X, Zhao P, et al. Autologous tumor lysate pulsed dendritic cell immunotherapy with cytokineinduced killer cells improves survival in gastric and colorectal cancer patients[J]. PLoS One, 2014, 9(4): 93886. [5] Zhang K, Gao PF, Yu PW, et al. Study on biological characters of SGC7901 gastric cancer celldendritic cell fusion vaccines[J]. World J Gastroenterol, 2006, 12(21): 3438-3441. [6] Linn YC, Hui KM. Cytokineinduced NKlike T cells: from bench to bedside[J]. Biomed Biotechnol, 2010, 20(10): 43-54. [7] Ishigami S, Arigami T, Uchikado Y, et al. IL32 expression is an independent prognostic marker for gastric cancer[J].Med Oncol, 2013, 30(2): 472-480. [8] Lissoni P, Brivio F, Ferrante R, et al. Circulating immature and mature dendritic cells in relation to lymphocyte subsets in patients with gastrointestinal tract cancer[J]. Int J Biol Markers, 2000, 15(1): 22-25. |
[1] | Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343. |
[2] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[3] | Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165. |
[4] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[5] | Shao Huifang, Wang Xuehong, Lu Yongfu.Mechanism of action and clinical significance of CST1 in the progression of gastric cancer[J]. Journal of International Oncology, 2023, 50(8): 489-492. |
[6] | Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu.Level of serum FABP1 and its relationship withHelicobacter pyloriinfection in patients with gastric cancer[J]. Journal of International Oncology, 2023, 50(6): 336-341. |
[7] | Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin.lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway[J]. Journal of International Oncology, 2023, 50(4): 202-207. |
[8] | Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen.Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185. |
[9] | Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen.Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 112-116. |
[10] | Yang Jun, Li Rong, Zeng Jianchang.Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(2): 82-86. |
[11] | Deng Lili, Duan Xingyu, Li Baozhong.Advances of anti-HER2 targeted drugs and combined therapeutic regimens for gastric and esophagogastic adenocarcinoma[J]. Journal of International Oncology, 2023, 50(12): 751-757. |
[12] | Li Jiayi, Wang Yue, Shang Lanlan, Xu Xing, Zhao Yan.Practice and prospect of artificial intelligence in diagnosis and treatment of gastric cancer[J]. Journal of International Oncology, 2023, 50(11): 677-682. |
[13] | Yu Xiaopeng, Feng Qingqing, Zhao Wenfei, Zhao Wenwen, Wei Hongmei.Application of targeted therapy combined with immune checkpoint inhibitors in the treatment of HER2 positive advanced gastric cancer[J]. Journal of International Oncology, 2023, 50(10): 631-635. |
[14] | Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281. |
[15] | Liu Cantong, Huang Xinyi, Chen Liuyi, Chen Hao, Peng Yuhui, Huang Xuchun.Level and diagnostic value of serum insulin-like growth factor binding protein 7 in patients with gastric cancer[J]. Journal of International Oncology, 2022, 49(12): 724-728. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||